Argent BioPharma Jumps 86% After Bold AusCann Acquisition

Argent BioPharma Jumps 86% After Bold AusCann Acquisition

Argent BioPharma Expands with AusCann Deal On August 19, Argent BioPharma (ASX: RGT) announced it was buying AusCann’s assets, which include the 100% ownership of the Neuvis drug delivery platform, 48% of CannPal Animal Therapeutics, and part of 20% of ECC Pharm. This deal gives Argent new technology, more research data, and access to the…

Argent Biopharma inks deal to acquire AusCann assets and IP

Argent BioPharma has entered into a binding agreement to acquire the core operating assets and intellectual […] The post Argent Biopharma inks deal to acquire AusCann assets and IP appeared first on Cannabiz.